Abstract
Acute coronary syndromes (ACS) continue to have a large impact on morbidity and mortality in the United States. Over the last two decades, there have been several advancements in the care of patients with ACS. The use of combined antiplatelet and anticoagulants and early invasive risk stratification in high risk patients has improved the rates of major adverse cardiovascular events. However, this treatment strategy increases the risk for bleeding. Studies have found an association between bleeding and subsequent mortality and morbidity in ACS patients; therefore, minimizing bleeding risk has become a priority. This review describes the prevalence of bleeding during ACS management, risk for bleeding, and strategies to reduce bleeding risk.
Keywords: Bleeding, acute coronary syndrome, mortality, antithrombotic and antiplatelet therapy, bleeding risk, CRUSADE, hemorrhagic complication, aspirin, anticoaguant
Current Drug Targets
Title: Bleeding and Acute Coronary Syndromes: Defining, Predicting, and Managing Risk and Outcomes
Volume: 12 Issue: 12
Author(s): Sharif A. Halim and Sunil V. Rao
Affiliation:
Keywords: Bleeding, acute coronary syndrome, mortality, antithrombotic and antiplatelet therapy, bleeding risk, CRUSADE, hemorrhagic complication, aspirin, anticoaguant
Abstract: Acute coronary syndromes (ACS) continue to have a large impact on morbidity and mortality in the United States. Over the last two decades, there have been several advancements in the care of patients with ACS. The use of combined antiplatelet and anticoagulants and early invasive risk stratification in high risk patients has improved the rates of major adverse cardiovascular events. However, this treatment strategy increases the risk for bleeding. Studies have found an association between bleeding and subsequent mortality and morbidity in ACS patients; therefore, minimizing bleeding risk has become a priority. This review describes the prevalence of bleeding during ACS management, risk for bleeding, and strategies to reduce bleeding risk.
Export Options
About this article
Cite this article as:
A. Halim Sharif and V. Rao Sunil, Bleeding and Acute Coronary Syndromes: Defining, Predicting, and Managing Risk and Outcomes, Current Drug Targets 2011; 12(12) . https://dx.doi.org/10.2174/138945011797635876
DOI https://dx.doi.org/10.2174/138945011797635876 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
CD147: A Novel Modulator of Inflammatory and Immune Disorders
Current Medicinal Chemistry Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Current Vascular Pharmacology Inflammatory Reactions and Hydrocortisone in the Setting of Cardiac Surgery: An Overview
Cardiovascular & Hematological Agents in Medicinal Chemistry Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Animal Models of Gastric Bleeding Induced by Dual Antiplatelet Therapy Using Aspirin and Clopidogrel - Prophylactic Effect of Antiulcer Drugs
Current Pharmaceutical Design Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design New Frontiers in the Therapeutic Management of Transplant Rejection
Current Pharmaceutical Design Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease
Current Vascular Pharmacology Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Current Pharmaceutical Design QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Lone Atrial Fibrillation: Electrophysiology, Risk Factors, Catheter Ablation and Other Non-pharmacologic Treatments
Current Pharmaceutical Design Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Advanced Diabetes Care: Three Levels of Prediction, Prevention & Personalized Treatment
Current Diabetes Reviews Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics